Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2006-05-23
2006-05-23
Li, Ruixiang (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S002600, C514S012200
Reexamination Certificate
active
07048919
ABSTRACT:
The present invention demonstrates the biological function of a newly identified osteoclast-secreted protein. This protein, mim-1, has sequence homology with but is distinct from a previously identified neutrophil chemokine protein. Mim-1 may be a key signaling protein secreted by osteoclasts that regulates recruitment and/or differentiation of osteoblast and osteoclast precursor cells. This protein may also serve to maintain osteoclasts in a relatively inactive state prior to secretion. This mechanism is essential for regulating the mass and structural integrity of bone. This protein or an analog and/or antagonists of this protein will have potential therapeutic potential in the treatment of a variety of pathological bone diseases including osteoporosis and metastatic bone diseases.
REFERENCES:
Ness et al, The ν-myb oncogene product binds to and activates the promyelocyte-specific mim-1 gene. Cell 59: 1115-1125, 1989.
Yamada et al, p.33, an endogenous target protein for arginine-specific ADP-ribosyltransferase in chicken polymorphonuclear leukocytes, is highly homologous to mim-1 protein (myb-induced myeloid protein-1). FEBS Lett. 311:203-205, 1992.
McDonald Jay M.
McKenna Margaret A.
Williams John P.
Adler Benjamin Aaron
Li Ruixiang
The UAB Research Foundation
LandOfFree
Osteoclast secreted chemokine and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Osteoclast secreted chemokine and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteoclast secreted chemokine and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3560452